Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEF3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $32,147
Award facts
- Contract value 100% obligated
- $32,147.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,147.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. This firm fixed-price delivery order was awarded on January 13, 2026, with an ultimate completion date of February 4, 2026, and does not utilize a set-aside designation. The contract was executed without a set-aside, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. As the sole awardee, DMS Pharmaceutical Group will fulfill this pharmaceutical supply requirement for Department of Defense medical operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.999 billion contract vehicle awarded in November 2025 with a completion date of December 31, 2036. The PPV-G GEN V initiative represents a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical consumable supplies to support military healthcare facilities globally. DMS Pharmaceutical Group's established performance history across multiple therapeutic categories and product lines, including specialty biologics and branded medications, positions the company as a critical supplier within the federal pharmaceutical supply chain for Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FMEF3?
SPE2DR26FMEF3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FMEF3 worth?
The government has obligated $32,147 on SPE2DR26FMEF3.
Is contract SPE2DR26FMEF3 an order under another contract?
Yes. SPE2DR26FMEF3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEF3 competed?
The extent of competition for SPE2DR26FMEF3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award